This study will treat patients with such severe lower leg ischemia or vascular compromise that they have pain at rest. The goal is to compare treatment of the patient's painful disorder by injecting cells into the calf of the leg and testing for circulatory improvement. A treatment will given at random to two groups and will be injection into the calf muscle with ALD-301 (specially processed stem and progenitor cells) from the patient's own bone marrow, or with cells processed by more routine that minimally purifies the cells. The study goal is to see if the ALD-301 cells are more effective in generating new small blood vessels to improve the circulation to the affected leg.
Patients will be recruited who have critical limb ischemia with pain at rest. The study will select patients for treatment and follow them for three months after intervention. The treatment will consist of drawing about 2/3 of a cup of bone marrow from the patient's hip bone, then processing the collected bone marrow will be as follows: * The test group's bone marrow will be processed and sorted to identify the aldehyde dehydrogenase bright ALDH-br stem and progenitor cells (ALD-301). These cells will be injected into the calf muscle of the patient in clinic. * The control group will have the same amount of bone marrow collected but it will undergo a simpler process to isolate the mononuclear cells from the whole bone marrow, removing most of the red cells and granulocytes from cell preparation for injection. The patients will be monitored for adverse events related to this process to determine the safety of the approach. They will also be tested at intervals during the study to compare baseline values of each patient with the post-treatment values of: 1. ankle-brachial index of systolic blood pressure 2. the transcutaneous oxygen measurements obtained from the skin of the treated leg 3. the patient's perception of his/her quality of life as measured by two different, validated questionnaires 4. Measurements of of heel/foot ulcers, if present, to monitor degree of healing if it occurs 5. the patient's perception of his/her level of pain in the leg The patients will receive a call at 6 months to report on additional life events following the study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
20
Surgery
Cardiology PC
Birmingham, Alabama, United States
Saint Joseph's Research Institute
Atlanta, Georgia, United States
University of Indiana at Indianapolis
Indianapolis, Indiana, United States
Duke University Medical Center
Durham, North Carolina, United States
Texas Heart Institute, Stem Cell Center, 6770 Bertner, St Luke's Episcopal Hospital
Houston, Texas, United States
adverse events
Time frame: 6 months
ankle-brachial systolic pressure index
Time frame: 3 mo
transcutaneous oxygen value (mm Torr)
Time frame: 3 mo
quality of life (questionnaires)
Time frame: 3 mo
size of lower extremity ulcer(s)
Time frame: 3 mo
peripheral nerve conduction exam
Time frame: 3 mo
level of pain at rest (questionnaire)
Time frame: 3 mo
limb clinical status
Time frame: 3 mo
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.